Kaliumphosphat B. Braun

Dipotassium phosphate and potassium dihydrogen phosphate, the active ingredients in Kaliumphosphat B. Braun, are electrolyte/mineral supplements presented as a sterile solution for injection for intravenous use. They are employed to correct low potassium and phosphate levels and to provide electrolyte support in patients undergoing surgery or experiencing critical illness.

GNH USA supplies Kaliumphosphat B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring timely delivery and regulatory compliance.

Kaliumphosphat B. Braun is used to replace deficient electrolytes in several clinical situations. - Hypophosphatemia: restores serum phosphate concentrations to support cellular energy metabolism. - Hypokalemia: replenishes potassium stores to maintain cardiac rhythm and neuromuscular function. - Peri‑operative electrolyte replacement: provides potassium and phosphate ions to stabilise electrolyte balance during surgery or critical illness.

Kaliumphosphat B. Braun may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Infusion site pain or irritation. - Phlebitis or vein inflammation. - Nausea or mild gastrointestinal discomfort. - Transient elevation of serum potassium. - Mild hyperphosphatemia. - Flushing or warmth at the injection site.

Serious or Rare Side Effects: - Severe hyperkalemia leading to cardiac arrhythmia. - Marked hyperphosphatemia causing calcium‑phosphate precipitation. - Anaphylactic or severe hypersensitivity reaction. - Tissue necrosis if the solution extravasates. - Life‑threatening cardiac arrest. - Severe metabolic acidosis.

When using Kaliumphosphat B. Braun, clinicians should consider several safety measures. - Renal impairment: monitor serum potassium and phosphate levels closely. - Cardiac disease: assess arrhythmia risk before administration. - Concurrent IV potassium chloride: avoid simultaneous infusion to prevent hyperkalemia. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Infusion rate: administer slowly as recommended to reduce local irritation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kaliumphosphat B. Braun can interact with other medicines, requiring attention to avoid clinically significant effects.

Major Interactions (Avoid): - Concurrent IV potassium chloride: may cause dangerous hyperkalemia. - Calcium gluconate infusion: can precipitate calcium‑phosphate complexes. - Aluminum‑containing antacids: bind phosphate, reducing therapeutic efficacy. - Loop diuretics: increase renal electrolyte loss, worsening imbalance.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may elevate potassium levels, requiring monitoring. - Beta‑blockers: can mask symptoms of hyperkalemia. - Insulin therapy: drives potassium intracellularly, potentially altering serum levels.